MINERVA PEDIATRICA, vol.70, no.3, pp.252-259, 2018 (SCI-Expanded)
Article / Article
Science Citation Index Expanded (SCI-EXPANDED), Scopus
Palivizumab, Prevention and control, Asthma, Respiratory syncytial virus infections, PREMATURE-INFANTS, RSV BRONCHIOLITIS, FOLLOW-UP, INFECTION, RIBAVIRIN, ALLERGY, RISK, IGE, CHILDREN, THERAPY
Ondokuz Mayıs University Affiliated:
BACKGROUND: Respiratory syncytial virus (RSV) infection is a disease commonly encountered during childhood and it may relapse. An experience in the early childhood would induce asthma development in the future. Palivizumab has a proven efficacy for the RSV prophylaxis so it may prevent asthma. Our aim was to evaluate the possible protective effect of palivizumab on the development of asthma by using the modified Asthma Predictive Index (mAPI).